Vertex Pharmaceuticals Short Interest Ratio and Short Volume

+1.20 (+0.64 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.21 million shs
Average Volume2.04 million shs
Market Capitalization$48.85 billion
P/E Ratio24.84
Dividend YieldN/A

Vertex Pharmaceuticals (NASDAQ:VRTX) Short Interest Data

Current Short Volume4,830,000 shares
Previous Short Volume5,040,000 shares
Change Vs. Previous Month-4.17%
Dollar Volume Sold Short$967.40 million
Short Interest Ratio / Days to Cover2.0
Last Record DateAugust, 31 2021
Outstanding Shares259,428,000 shares
Float Size257,760,000 shares
Short Percent of Float1.87%
Today's Trading Volume2,214,404 shares
Average Trading Volume2,035,394 shares
Today's Volume Vs. Average8.79%

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Vertex Pharmaceuticals ?

Sign up to receive the latest short interest report for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Vertex Pharmaceuticals (NASDAQ:VRTX) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/20214,830,000 shares $967.40 million -4.2%1.9%2 $200.29
8/13/20215,040,000 shares $979.57 million +20.3%2.0%2.1 $194.36
7/30/20214,190,000 shares $844.62 million +2.4%1.6%1.8 $201.58
7/15/20214,090,000 shares $818.37 million +0.5%1.6%1.9 $200.09
6/30/20214,070,000 shares $820.63 million -10.0%1.6%1.9 $201.63
6/15/20214,520,000 shares $854.14 million +11.6%1.8%2.3 $188.97
5/28/20214,050,000 shares $844.95 million -1.5%1.6%2.5 $208.63
5/14/20214,110,000 shares $880.98 million -11.2%N/A2.5 $214.35
4/30/20214,630,000 shares $980.91 million -5.3%N/A2.5 $211.86
4/15/20214,890,000 shares $1.06 billion +15.1%N/A2.4 $217.13
3/31/20214,250,000 shares $905.21 million -14.7%N/A2.1 $212.99
3/15/20214,980,000 shares $1.07 billion +14.5%N/A2.5 $214.33
2/26/20214,350,000 shares $926.46 million +9.0%N/A2.2 $212.98
2/12/20213,990,000 shares $839.88 million +15.0%N/A2 $210.50
1/29/20213,470,000 shares $798.24 million +5.5%N/A1.8 $230.04
1/15/20213,290,000 shares $743.93 million -2.4%N/A1.8 $226.12
12/31/20203,370,000 shares $784.13 million +3.7%N/A1.6 $232.68
12/15/20203,250,000 shares $741.42 million +21.3%N/A1.5 $228.13
11/30/20202,680,000 shares $607.58 million -2.6%N/A1.3 $226.71
10/30/20202,920,000 shares $604.47 million -7.6%N/A1.6 $207.01
10/15/20203,160,000 shares $857.81 million -6.8%N/A1.9 $271.46
9/30/20203,390,000 shares $922.49 million +11.5%N/A2.7 $272.12
9/15/20203,040,000 shares $811.22 million -9.3%N/A2.3 $266.85
8/31/20203,350,000 shares $935.05 million +4.0%N/A2.4 $279.12
8/14/20203,220,000 shares $860.67 million -4.2%N/A2 $267.29

Institutional Investors Shorting Vertex Pharmaceuticals (NASDAQ:VRTX)

This table shows institutional investors, funds, and major shareholders that have reported short positions as of their most recent reporting period. Most commonly, these investors have purchased put options on shares of Vertex Pharmaceuticals. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Reporting DateInvestor NameShares Shorted (Previous)Shares Shorted (Current)Position ChangePosition Size
9/13/2021Bank of America Corp DE193,100192,000-0.6%$38,713.00
8/31/2021Pathstone Family Office LLCN/A2,289N/A$462.00
8/20/2021Jefferies Group LLC25,00025,000No Change$5,041.00
8/18/2021Ikarian Capital LLC200,0000-100.0%$0.00
8/17/2021Wells Fargo & Company MNN/A100,000N/A$20,163.00
8/17/2021Walleye Trading LLC14,50010,300-29.0%$2,077.00
8/17/2021Weiss Multi Strategy Advisers LLCN/A5,000N/A$1,008.00
8/17/2021Millennium Management LLC248,100108,300-56.3%$21,837.00
8/17/2021Pathstone Family Office LLCN/A2,289N/A$462.00
8/17/2021Parallax Volatility Advisers L.P.22,0000-100.0%$0.00
8/17/2021Caas Capital Management LP100,0000-100.0%$0.00
8/17/2021Citadel Advisors LLC302,400665,300+120.0%$134,144.00
8/16/2021Bank of America Corp DE193,100192,000-0.6%$38,713.00
8/16/2021Credit Suisse AG21,90016,700-23.7%$3,367.00
8/16/2021Maven Securities LTD3,7001,200-67.6%$242.00
8/16/2021Jefferies Group LLC25,0002,500,000+9,900.0%$5,041.00
8/16/2021Capula Management Ltd9,5000-100.0%$0.00
8/16/2021Goldman Sachs Group Inc.73,900158,900+115.0%$32,039.00
8/16/2021Allianz Asset Management GmbH4,2003,600-14.3%$726.00
8/13/2021PEAK6 Investments LLC73,30097,100+32.5%$19,578.00
8/13/2021Lombard Odier Asset Management USA CorpN/A50,000N/A$10,082.00
8/13/2021SpiderRock Advisors LLC92,00027,000-70.7%$5,265.00
8/12/2021SG Americas Securities LLCN/A100,000N/A$2,890.00
8/12/2021JPMorgan Chase & Co.223,90039,100-82.5%$7,884.00
8/12/2021Simplex Trading LLC1,00161,900+6,083.8%$12,480.00
8/11/2021HAP Trading LLCN/A13,800N/A$244.00
8/11/2021Susquehanna International Group LLP860,900923,000+7.2%$186,104.00
8/10/2021Group One Trading L.P.185,300166,300-10.3%$33,531.00
8/10/2021BNP Paribas Arbitrage SA1,0301,030No Change$20,768.00
8/10/2021Citigroup Inc.N/A15,600N/A$3,145.00
8/6/2021Wolverine Trading LLC23,60042,600+80.5%$8,383.00
7/31/2021Cutler Group LP1,700200-88.2%$1.00

Vertex Pharmaceuticals (NASDAQ:VRTX) Short Interest FAQ

speech bubbles
speech bubbles

What is Vertex Pharmaceuticals' current short interest?

Short interest is the volume of Vertex Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 4,830,000 shares of VRTX short. 1.87% of Vertex Pharmaceuticals' shares are currently sold short. Learn More on Vertex Pharmaceuticals' current short interest.

What is a good short interest ratio for Vertex Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Vertex Pharmaceuticals currently has a short interest ratio of 2.0. Learn More on a good short interest ratio for Vertex Pharmaceuticals

Which institutional investors are shorting Vertex Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Vertex Pharmaceuticals: Bank of America Corp DE, Pathstone Family Office LLC, Jefferies Group LLC, Ikarian Capital LLC, Wells Fargo & Company MN, Walleye Trading LLC, Weiss Multi Strategy Advisers LLC, Millennium Management LLC, Pathstone Family Office LLC, Parallax Volatility Advisers L.P., Caas Capital Management LP, Citadel Advisors LLC, Bank of America Corp DE, Credit Suisse AG, Maven Securities LTD, Jefferies Group LLC, Capula Management Ltd, Goldman Sachs Group Inc., Allianz Asset Management GmbH, PEAK6 Investments LLC, Lombard Odier Asset Management USA Corp, SpiderRock Advisors LLC, SG Americas Securities LLC, JPMorgan Chase & Co., Simplex Trading LLC, HAP Trading LLC, Susquehanna International Group LLP, Group One Trading L.P., BNP Paribas Arbitrage SA, Citigroup Inc., Wolverine Trading LLC, and Cutler Group LP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Vertex Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.87% of Vertex Pharmaceuticals' floating shares are currently sold short.

Is Vertex Pharmaceuticals' short interest increasing or decreasing?

Vertex Pharmaceuticals saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 4,830,000 shares, a decrease of 4.2% from the previous total of 5,040,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Vertex Pharmaceuticals' float size?

Vertex Pharmaceuticals currently has issued a total of 259,428,000 shares. Some of Vertex Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vertex Pharmaceuticals currently has a public float of 257,760,000 shares.

How does Vertex Pharmaceuticals' short interest compare to its competitors?

1.87% of Vertex Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Vertex Pharmaceuticals: Amgen Inc. (1.98%), Gilead Sciences, Inc. (0.00%), Regeneron Pharmaceuticals, Inc. (1.33%), Biogen Inc. (1.60%), Seagen Inc. (1.45%), Alnylam Pharmaceuticals, Inc. (0.00%), Exact Sciences Co. (0.00%), Novavax, Inc. (8.25%), Repligen Co. (3.08%), and Incyte Co. (2.72%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Square, Inc. ($9.81 billion), S&P Global Inc. ($7.52 billion), Advanced Micro Devices, Inc. ($7.18 billion), Charter Communications, Inc. ($6.21 billion), Wayfair Inc. ($4.60 billion), Zoom Video Communications, Inc. ($3.23 billion), Uber Technologies, Inc. ($3.11 billion), Palo Alto Networks, Inc. ($2.74 billion), Teladoc Health, Inc. ($2.52 billion), and Etsy, Inc. ($2.16 billion). View all of the most shorted stocks.

What does it mean to sell short Vertex Pharmaceuticals stock?

Short selling VRTX is an investing strategy that aims to generate trading profit from Vertex Pharmaceuticals as its price is falling. Vertex Pharmaceuticals' stock is trading up $1.20 today. To short Vertex Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Vertex Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Vertex Pharmaceuticals?

A short squeeze for Vertex Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VRTX, which in turn drives the price of the stock up even further.

How often is Vertex Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRTX, twice per month. The most recent reporting period available is August, 31 2021.

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.